The application of lanreotide autogel for the treatment of acromegaly

Autor:	I A Ilovaĭskaia
Rok vydání:	2010
Předmět:	Pediatrics medicine.medical_specialty business.industry Endocrinology Diabetes and Metabolism Lanreotide Autogel Growth hormone medicine.disease Surgery Clinical Practice Premature death Somatostatin Acromegaly medicine Somatostatin analog business
Zdroj:	Problems of Endocrinology. 56:55-62
ISSN:	2308-1430 0375-9660
DOI:	10.14341/probl201056655-62
Popis:	The early diagnosis of acromegaly and timely initiation of the adequate treatment are of primary importance for the prevention of the undesired long-term effects of chronic overproduction of growth hormone and insulin-like growth factor-1. Over half of the patients presenting with acromegaly are in need of sustainable treatment with somatostatin analogs that reduces the risk of premature death and helps to maintain quality of life. The new somatostatin analog lanreotide autogel recently introduced into clinical practice is known to effectively diminish secretion of both growth hormone and insulin-like growth factor-1. Moreover, it shows the ability to decrease the volume of somatotropinoms and is well tolerated by the patients. The intervals between injections of lanreotide autogel can be prolonged from 4 to 6-8 weeks. Its subcutaneous administration is technically easy which enables the majority of the patients to perform self-injections. Taken together, these advantages of lanreotide autogel considerably extend the opportunities for medical aid to the patients with acromegaly.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::92b499b8ebfb05146601b54b8fe5b863 https://doi.org/10.14341/probl201056655-62 Zobrazit plný text záznamu